SCM
TNXP icon

Sterling Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Sterling Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.19K Sell
450
-284
-39% -$4.37K ﹤0.01% 2628
2025
Q4 		$11.5K Buy
734
+123
+20% +$2.27K ﹤0.01% 2539
2025
Q3 		$14.8K Buy
611
+407
+200% +$15.1K ﹤0.01% 2290
2025
Q2 		$7.34K Buy
+204
New +$5.34K ﹤0.01% 2303

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sterling Capital Management's TNXP Position: Q1 2026 in Review

Sterling Capital Management reduced its Tonix Pharmaceuticals (TNXP) stake by 39% in Q1 2026, selling an estimated $4.37K and leaving 450 shares worth $6.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

Sterling Capital Management first reported a position in TNXP in Q2 2025 and has held it in 4 quarters since. The position peaked at $14.8K in Q3 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Sterling Capital Management held 450 shares of Tonix Pharmaceuticals worth $6.19K as of Q1 2026.
  • Sterling Capital Management sold 284 Tonix Pharmaceuticals shares in Q1 2026, an estimated $4.37K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2628 holding.
  • Sterling Capital Management first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Sterling Capital Management's Tonix Pharmaceuticals position peaked at $14.8K in Q3 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.